Sign in
Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock

Key facts

Who runs it
Inotrem
Where
Belgium, Denmark, Finland, France, Ireland, and Spain43 sites in 6 countriesChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
355 people enrolled
Started
13 Nov 2019
Ended
9 May 2023
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • nangibotide low dose
  • nangibotide high dose
  • placebo
Record updated
11 April 2023

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Provide written informed consent
  • Age 18 to 85 years (inclusive)
  • Documented or suspected infection: lung, abdominal or urinary tract infection (UTI) in the elderly (≥65 years)
  • Organ dysfunction defined as acute change in total SOFA score ≥ 2 points
  • Refractory hypotension requiring vasopressors to maintain MAP ≥65mm Hg despite adequate volume resuscitation
  • Hyperlactatemia (blood lactate >2 mmol/L or 18 mg/dL)

Who cannot take part

  • Previous episode of septic shock requiring vasopressor administration within current hospital stay
  • Underlying concurrent immunodepression with anti-CD52 alemtuzumab (Campath) or glucocorticoids >75 mg prednisone daily or equivalent for more than 7 days
  • Immunosuppressive therapy related to recent (<6 months) transplantation
  • Home oxygen therapy on a regular basis for > 6 h/day
  • Participation in another interventional study in the 3 months prior to randomization
  • Cancer chemotherapy (<3 months) implying an immunodepression
  • Shock of any other cause, e.g. hypotension related to gastrointestinal bleeding
  • Ongoing documented or suspected endocarditis, history of prosthetic heart valves
  • End-stage neurological disease
  • Known HIV infection with low CD4 cell count (<200) for at least 6 months
  • Known pregnancy (positive urine or serum pregnancy test)
  • Prolonged QT syndrome
  • End-stage cirrhosis (Child Pugh Class C)
  • Acute Physiology and Chronic Health Evaluation (APACHE II) score <15 or ≥ 34
  • Recent cardiopulmonary resuscitation (CPR) (within current hospital stay)
  • Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg
  • Moribund patients
  • Decision to limit full care taken before obtaining informed consent

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.

The 3 groups in the trial

  • nangibotide 1Treatment being tested

    Treatment with study drug at at dose of 0.3mg/kg/hr

    Treatment: nangibotide low dose

  • nangibotide 2Treatment being tested

    Treatment with study drug at at dose of 1.0mg/kg/hr

    Treatment: nangibotide high dose

  • PlaceboPlacebo, for comparison

    Treatment with a matched placebo infusion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock. A Randomized, Double-blind, Placebo Controlled Dose Selection Study
Publications
Record updated
11 April 2023